Hill-Rom Holdings, Inc. (NYSE:HRC) Holdings Raised by Man Group plc
Man Group plc lifted its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 76.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 284,982 shares of the medical technology company’s stock after acquiring an additional 123,021 shares during the period. Man Group plc’s holdings in Hill-Rom were worth $32,354,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. FNY Investment Advisers LLC bought a new stake in shares of Hill-Rom during the fourth quarter valued at about $34,000. Lloyd Advisory Services LLC. bought a new stake in shares of Hill-Rom during the fourth quarter valued at about $41,000. TRUE Private Wealth Advisors bought a new stake in shares of Hill-Rom during the fourth quarter valued at about $41,000. Carroll Financial Associates Inc. bought a new stake in Hill-Rom in the fourth quarter worth about $52,000. Finally, Duncker Streett & Co. Inc. bought a new stake in Hill-Rom in the fourth quarter worth about $148,000. Institutional investors and hedge funds own 84.52% of the company’s stock.
Several equities research analysts have commented on the stock. Morgan Stanley upgraded shares of Hill-Rom from an “equal” rating to an “equal weight” rating and boosted their price target for the stock from $113.00 to $138.00 in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $131.00 price target on shares of Hill-Rom in a research report on Friday, January 24th. Finally, Barclays upgraded shares of Hill-Rom from an “equal weight” rating to an “overweight” rating and set a $116.00 price target on the stock in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Hill-Rom presently has a consensus rating of “Buy” and a consensus price target of $122.60.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, January 24th. The medical technology company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.08 by $0.05. Hill-Rom had a net margin of 5.15% and a return on equity of 21.87%. The firm had revenue of $685.00 million for the quarter, compared to analysts’ expectations of $684.01 million. During the same period in the previous year, the business earned $1.02 earnings per share. Hill-Rom’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts predict that Hill-Rom Holdings, Inc. will post 5.55 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Monday, March 23rd will be paid a $0.22 dividend. The ex-dividend date is Friday, March 20th. This represents a $0.88 dividend on an annualized basis and a yield of 0.92%. This is a boost from Hill-Rom’s previous quarterly dividend of $0.21. Hill-Rom’s dividend payout ratio (DPR) is currently 17.32%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Recommended Story: What is the definition of a trade war?
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.